 |
|
What's New
|
Amex: ANX 0.424 +0.0117
|
May 13, 2008
ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 12, 2008
ADVENTRX Pharmaceuticals Reports First Quarter 2008 Financial Results
May 5, 2008
ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
April 15, 2008
ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
April 9, 2008
ADVENTRX Appoints Vice President of Manufacturing
April 3, 2008
ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
March 31, 2008
ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
March 13, 2008
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
March 12, 2008
ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
March 10, 2008
Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
March 6, 2008
ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
February 25, 2008
Eric K. Rowinsky Joins ADVENTRX Board of Directors
February 7, 2008
ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
February 5, 2008
ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
January 31, 2008
ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
January 30, 2008
ADVENTRX Announced Consolidation of Clinical and Management Positions
January 14, 2008
ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission Guidance
|
